Results 151 to 160 of about 112,050 (329)

2-acetylphenol analogs as potent reversible monoamine oxidase inhibitors

open access: yesDrug Design, Development and Therapy, 2015
Lesetja J Legoabe,1 Anél Petzer,1 Jacobus P Petzer1,21Centre of Excellence for Pharmaceutical Sciences, 2Department of Pharmaceutical Chemistry, School of Pharmacy, North-West University, Potchefstroom, South AfricaAbstract: Based on a previous ...
Legoabe LJ, Petzer A, Petzer JP
doaj  

Salvia coccinea and Apigenin: A Natural Treasure of Lamiaceae in Pharmacological Innovation

open access: yesFood Science &Nutrition, Volume 14, Issue 2, February 2026.
Salvia coccinea is rich in bioactive phytochemicals, notably the flavonoid apigenin, offering strong antioxidant, anti‐inflammatory, and antimicrobial effects. By modulating inflammatory and oxidative pathways, it shows potential for managing chronic diseases.
Muhammad Usman Khalid   +7 more
wiley   +1 more source

Neuro‐Immune Crosstalk: Molecular Mechanisms, Biological Functions, Diseases, and Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 2, February 2026.
Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo   +11 more
wiley   +1 more source

Oxidative Stress: Molecular Mechanisms, Diseases, and Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 2, February 2026.
Oxidative stress occurs when the reactive oxygen species (ROS) production overwhelms the ROS scavenging, which lead to genomic instability, epigenetic regulation, proteostasis imbalance, and lipid peroxidation, subsequently causing the occurrence and development of numerous diseases. ABSTRACT Although the physiological level of reactive oxygen species (
Yi Qin   +10 more
wiley   +1 more source

The role of rasagiline in the treatment of Parkinson’s disease

open access: yesClinical Interventions in Aging, 2010
Julie Leegwater-Kim1, Elena Bortan21Tufts University School of Medicine and Department of Neurology, Lahey Clinic, Burlington, MA, USA; 2Department of Neurology, Lahey Clinic, Burlington, MA, USAAbstract: Parkinson’s disease (PD) is the second most
Julie Leegwater-Kim, Elena Bortan
doaj  

Down-regulation of serotonergic genes expression in the raphe nuclei of midbrain under chronic social defeat stress in male mice [PDF]

open access: yes, 2011
Background: There is ample experimental evidence supporting the hypothesis that the brain serotonergic system is involved in the control of chronic social defeat stress (CSDS), depression and anxiety.
Maxim L. Filipenko   +3 more
core   +1 more source

Bone Metastasis: Molecular Mechanisms, Clinical Management, and Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 2, February 2026.
This figure emphasizes current understanding of the regulatory networks, approach of diagnose, available preclinical models and clinical management of bone metastasis. to guide future therapeutic development. A deep understanding of these aspects enables the prevention of bone metastasis and the implementation of effective therapeutic strategies ...
Jingyuan Wen   +5 more
wiley   +1 more source

In Vitro Evaluation of Novel Furo[3,2-c]coumarins as Cholinesterases and Monoamine Oxidases Inhibitors

open access: yesMolecules
Coumarin represents a privileged structural motif that is quite common in nature-derived and synthetic bioactive molecules. Some of us have recently described the straightforward preparation of complex furo[3,2-c]coumarins through a sequential double ...
Mariagrazia Rullo   +10 more
doaj   +1 more source

Subcutaneous Levodopa in Parkinson's Disease: A Systematic Review and Meta‐Analysis

open access: yesEuropean Journal of Neurology, Volume 33, Issue 2, February 2026.
ABSTRACT Background Many Parkinson's disease patients receiving oral levodopa/carbidopa experience a troublesome wearing off effect. Higher doses to mitigate OFF‐time are limited by adverse effects occurring at peak dopamine levels, particularly dyskinesia.
Matthew Burton   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy